Back
News
1 min de lecture

[Press Release] Accelarated Scientific Advise from European Medicines Adgency EMA for XAV19 Market Authorisation

  • contact@xenothera.com
  • Auteur
    contact@xenothera.com
  • Publié
    18 juillet 2021

Articles récents

[Press Alert] XENOTHERA announces the efficacy of its XAV-19 antibody against the BQ.1.1variant.

December 19, 2022. # Download our press alert (english version) # Télécharger...

More

[Press Release] XAV-19: end of EUROXAV clinical trial and positive trends for the XENOTHERA antibody.

December 16,2022. # Download our press release (english version) # Télécharger notre...

More

[Newsletter] XENONEWS

November 2022. >> Official XENOTHERA’s newsletter /Lettre d’information officielle de XENOTHERA <<...

More